Literature DB >> 21625238

Evidence-based management of upper tract urolithiasis in the spinal cord-injured patient.

S Ramsey1, C McIlhenny.   

Abstract

OBJECTIVE: The objective is to review the published literature on the aetiology and evidence-based management of stone disease in the spinal cord-injured patient.
METHODS: A PubMed and Medline search was performed using the terms 'spinal cord injury', 'paraplegia', 'stone', 'nephrolithiasis', 'urolithiasis', 'calculus', 'spinal cord injury' or 'paraplegia' with 'SWL', 'ureteroscopy', 'chemolysis' and 'PCNL.' The Cochrane database, the National Institute for Clinical Excellence guidelines and the Scottish Intercollegiate guidelines were searched using the terms 'spinal cord injury' and 'urolithiasis' and 'nephrolithiasis'.
RESULTS: A total of 32 papers were identified, mainly case series or case-cohort studies with few contemporary papers. The risk of developing a renal stone after spinal cord injury (SCI) is between 7 and 20% over a period of 8-10 years. Stone formation may be related to early demineralisation of bone or chronic infection. Biochemical abnormalities are not significantly different between stone-forming and non-stone forming patients, though these patients differ from healthy controls. Presentation may be atypical, but is most commonly recurrent urinary tract infection. Treatment may be complicated by lower limb contractures limiting retrograde access. Several case series report success with shock wave lithotripsy varying from 50 to 70%, though comparisons are limited by heterogeneous indications and reporting. Percutaneous nephrolithotomy remains the gold standard for stones measuring 2 cm and above. Stone-free rates of 90% have been reported, though surgery was often complex with higher complication rates.
CONCLUSION: Management of upper urinary tract stones in patients with SCI is complex regarding surgical technique, post-operative care and recurrence rates. Further contemporary case series must use standardised reporting tools to allow valid comparisons.

Entities:  

Mesh:

Year:  2011        PMID: 21625238     DOI: 10.1038/sc.2011.50

Source DB:  PubMed          Journal:  Spinal Cord        ISSN: 1362-4393            Impact factor:   2.772


  7 in total

1.  Complications of surgical management of upper tract calculi in spina bifida patients: analysis of nationwide data.

Authors:  Hsin-Hsiao S Wang; John S Wiener; Michael N Ferrandino; Michael E Lipkin; Jonathan C Routh
Journal:  J Urol       Date:  2014-09-28       Impact factor: 7.450

Review 2.  Surgical management of urolithiasis in spinal cord injury patients.

Authors:  Philippe Nabbout; Gennady Slobodov; Daniel J Culkin
Journal:  Curr Urol Rep       Date:  2014-06       Impact factor: 3.092

3.  Large subcapsular hematoma following ureteroscopic laser lithotripsy of renal calculi in a spina bifida patient: lessons we learn.

Authors:  Subramanian Vaidyanathan; Azi Samsudin; Gurpreet Singh; Peter L Hughes; Bakul M Soni; Fahed Selmi
Journal:  Int Med Case Rep J       Date:  2016-08-24

Review 4.  Congenital causes of neurogenic bladder and the transition to adult care.

Authors:  Christopher J Loftus; Hadley M Wood
Journal:  Transl Androl Urol       Date:  2016-02

5.  Trends in renal calculus composition and 24-hour urine analyses in patients with neurologically derived musculoskeletal deficiencies.

Authors:  Lee A Hugar; Ilan Kafka; Thomas W Fuller; Hassan Taan; Timothy D Averch; Michelle J Semins
Journal:  Int Braz J Urol       Date:  2019 May-Jun       Impact factor: 1.541

6.  Ureteroscopy in patients with spinal cord injury: outcomes from a spinal injury unit and a review of literature.

Authors:  Sarah Prattley; Rachel Oliver; Francesca New; Melissa Davies; James Brewin
Journal:  Transl Androl Urol       Date:  2019-09

7.  Surgical decompression improves recovery from neurological deficit and may provide a survival benefit in patients with diffuse large B-cell lymphoma-associated spinal cord compression: a case-series study.

Authors:  Ching-Ming Chang; Hung-Chieh Chen; Youngsen Yang; Ren-Ching Wang; Wen-Li Hwang; Chieh-Lin Jerry Teng
Journal:  World J Surg Oncol       Date:  2013-04-19       Impact factor: 2.754

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.